EpiAxis executives attend US biotech conferences

EpiAxis executives attend US biotech conferences

It’s an exciting month for EpiAxis Therapeutics as we return to face-to-face biotech conferences after more than two years of virtual attendance. Chairman Dr David Fuller is currently representing EpiAxis at the ASCO 2022 Annual Meeting in Chicago; while CEO Dr...
EpiAxis Therapeutics presents at Bioshares Biotech Summit

EpiAxis Therapeutics presents at Bioshares Biotech Summit

EpiAxis Therapeutics was pleased to attend and present at the 16th Bioshares Biotech Summit this month in Albury, NSW. BioShares is a life science conference mainly targeting ASX-listed Australian biotech companies, biotech investors, fund managers and brokers and...
EpiAxis highlights – April 2022

EpiAxis highlights – April 2022

April was an exciting month for EpiAxis Therapeutics, with Dr Darren Saunders joining the company as inaugural Chief Science Officer and CEO Dr Jeremy Chrisp updating investors in Australia and China on the company’s progress in the epigenetic space. Dr Saunders...
EpiAxis Therapeutics presents at ACCESS CHINA

EpiAxis Therapeutics presents at ACCESS CHINA

EpiAxis Therapeutics was thrilled to attend and present at the ACCESS CHINA Biotech Forum Spring Showcase 2022 earlier this month. ACCESS CHINA Biotech Forum is one of the largest corporate access events in China. It provides opportunities for business development,...